| Chiesi Farmaceutici S.p.A. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120116091 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS - Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme. | 05-10-2012 |
| 20120101076 | CARBONATE DERIVATIVES FOR THE TREATMENT OF COUGH - The invention relates to use of certain quinuclidine carbonate derivatives as cough suppressants, particularly for treating patients with upper respiratory tract infections or asthma. | 04-26-2012 |
| 20120088763 | TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE - Compounds of formula (I) are inhibitors of p38 MAP kinase, useful as anti-inflammatory agents in the treatment of inter alia, diseases of the respiratory tract wherein; R | 04-12-2012 |
| 20120082727 | USE OF MAGNESIUM STEARATE IN DRY POWDER FORMULATIONS FOR INHALATION - Addition of magnesium stearate to a powder formulation for inhalation comprising carrier particles and an active ingredient bearing a group susceptible to hydrolysis is useful for inhibiting or reducing the chemical degradation of the active ingredient. | 04-05-2012 |
| 20120077809 | PYRIMIDOPYRIDAZINE DERIVATIVES USEFUL AS P38 MAPK INHIBITORS - A compound formula (IA) or (IB), or a pharmaceutically acceptable thereof; wherein the substituents are defined as in the claims, and their use as P38 MAP kinase. | 03-29-2012 |
| 20120055468 | METERED-DOSE INHALER ACTUATOR, METERED-DOSE INHALER AND METHOD OF USING THE SAME - An actuator for a metered-dose inhaler is provided. The actuator comprises a housing having a mouthpiece portion and a canister receiving portion configured to receive a canister. The actuator further comprises a member disposed within the housing and defining a valve stem receptacle configured to receive a valve stem of the canister. An orifice is formed in the member, which is in fluid communication with the valve stem receptacle and extending to a face of the member opposite to the valve stem receptacle. A longitudinal axis of the orifice is aligned with a longitudinal axis of the valve stem receptacle. At least one air inlet opening is provided in an outer shell of the housing so as to be spaced from an opening for receiving the canister and a mouthpiece opening. | 03-08-2012 |
| 20120055467 | METERED-DOSE INHALER AND METHOD OF USING THE SAME - A metered-dose inhaler includes at least one vessel and an actuator for receiving the at least one vessel. The at least one vessel includes a first reservoir containing a first formulation and a second reservoir containing a second formulation. The metered-dose inhaler is actuable when the at least one vessel is received by the actuator. The metered-dose inhaler is configured to simultaneously deliver a first metered dose of the first formulation and a second metered dose of the second formulation upon actuation. | 03-08-2012 |
| 20120034172 | PHARMACEUTICAL FORMULATION COMPRISING A PHOSPHODIESTERASE INHIBITOR - Pharmaceutical formulations to be administered by pressurized metered dose inhalers (pMDIs), comprising a compound of general formula (I) may be used for the treatment and/or prevention of inflammatory or obstructive airway diseases. | 02-09-2012 |
| 20120031403 | DRY POWDER FORMULATION COMPRISING A PHOSPHODIESTERASE INHIBITOR - Pharmaceutical formulations in the form of inhalable dry powder comprising particles of a phosphodiesterase-4 inhibitor as active ingredient are useful for the prevention and/or treatment of respiratory diseases, such as asthma and COPD. | 02-09-2012 |
| 20120027692 | PYRROLOPYRIMIDINEDIONE AND ITS THERAPEUTIC USE - The compound of formula (I) is an inhibitor of human neutrophil elastase, useful for inhalation treatment of pulmonary inflammation. | 02-02-2012 |
| 20120022163 | 1-(2-FLUOROBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID DERIVATIVES FOR THE THERAPY OF PRION DISEASES - Derivatives of 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid are useful for the prevention and/or treatment of prion diseases in animals and humans. | 01-26-2012 |
| 20120004258 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF - Quinuclidine carbonate derivatives act as muscarinic receptor antagonists and are effective for the prevention and/or treatment of a broncho-obstructive or inflammatory diseases. | 01-05-2012 |
| 20110319444 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF - Quinuclidine carbonate derivatives act as muscarinic receptor antagonists and are effective for the prevention and/or treatment of a broncho-obstructive or inflammatory diseases. | 12-29-2011 |
| 20110311461 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF - The present invention relates to alkaloid aminoester compounds which act as muscarinic receptor antagonists, processes for their preparation, compositions comprising them, and therapeutic uses thereof. | 12-22-2011 |
| 20110311459 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF - The present invention relates to alkaloid aminoester compounds which act as muscarinic receptor antagonists, processes for the preparation of such a compound, compositions which contain such a compound, and therapeutic uses of such a compound. | 12-22-2011 |
| 20110311458 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF - The present invention relates to alkaloid aminoester compounds which act as muscarinic receptor antagonists, processes for their preparation, compositions comprising them, and therapeutic uses thereof. | 12-22-2011 |
| 20110308519 | DRY POWDER FORMULATION COMPRISING AN ANTIMUSCARINIC DRUG - The invention provides dry powder formulations suitable for the inhalatory administration by means of a dry powder inhaler, comprising an antimuscarinic drug as active ingredient. The invention also provides processes for the preparation of such a formulation and method for the prevention and/or treatment of a wide range of conditions including respiratory disorders by administering such a formulation. | 12-22-2011 |
| 20110306650 | PROCESS FOR THE PREPARATION OF GLYCOPYRRONIUM CHLORIDE - The invention concerns a method for preparing glycopyrronium chloride, and its use in pharmaceutical applications. | 12-15-2011 |
| 20110305645 | CRYSTAL FORM OF GLYCOPYRRONIUM CHLORIDE - A new crystal form of threo glycopyrronium chloride is useful in pharmaceutical applications. | 12-15-2011 |
| 20110288175 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - 1-Phenylalkanecarboxylic acid derivatives, the processes for the preparation thereof and the use thereof in the treatment and/or prevention of neurodegenerative diseases such as Alzheimer's disease. | 11-24-2011 |
| 20110263711 | 1-(2-FLUOROBIPHENYL-4-YL)-ALKYL CARBOXYLIC ACID DERIVATIVES FOR THE THERAPY OF TRANSTHYRETIN AMYLOIDOSIS - Derivatives of 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid are capable of stabilizing the tetrameric native state of transthyretin for the prophylaxis and treatment of amyloidosis. | 10-27-2011 |
| 20110262547 | PROCESS FOR PREPARING CARRIER PARTICLES FOR DRY POWDERS FOR INHALATION - Carrier particles in which at least 60% of the surface is coated with magnesium stearate are useful for preparing dry powder formulations for inhalation. | 10-27-2011 |
| 20110262543 | PROCESS FOR PROVIDING PARTICLES WITH REDUCED ELECTROSTATIC CHARGES - Carrier particles for dry powder formulations for inhalation having reduced electrostatic charges are prepared. | 10-27-2011 |
| 20110245346 | NOVEL POLYMORPHS AND SALTS - Novel polymorphic forms and salts of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid are useful for the prevention or treatment of Alzheimer's Disease. | 10-06-2011 |
| 20110212912 | OPTIMISED FORMULATION OF TOBRAMYCIN FOR AEROSOLIZATION - The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium | 09-01-2011 |
| 20110201580 | PYRROLIDINE DERIVATIVES - The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, methods of preparing such compounds, pharmaceutical compositions comprising them, combinations and therapeutic uses thereof. More particularly, the invention relates to glucocorticosteroids that are derivatives of pyrrolidine. | 08-18-2011 |
| 20110150784 | COMBINATION THERAPY FOR COPD - Aerosol formulations comprising glycopyrronium chloride in combination with formoterol may be administered by means of a pressurized metered dose inhaler (pMDI) for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium chloride and the formoterol components. Optionally, the formulation may further comprise beclometasone dipropionate. | 06-23-2011 |
| 20110150783 | AEROSOL FORMULATION FOR COPD - Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions. | 06-23-2011 |
| 20110150782 | COMBINATION THERAPY FOR COPD - Aerosol formulations comprising glycopyrronium bromide in combination with formoterol are useful for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium bromide and the formoterol components. Optionally the formulation may further comprise beclometasone dipropionate. | 06-23-2011 |
| 20110146677 | AEROSOL FORMULATION FOR COPD - The stable aerosol solution formulations comprising glycopyrronium chloride are useful for administration to patients with COPD and other respiratory conditions. | 06-23-2011 |
| 20110144075 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS - Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme. | 06-16-2011 |
| 20110144070 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS - Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme. | 06-16-2011 |
| 20110139152 | ANTIBIOTIC MICROPARTICLES FOR INHALATION - Powder formulations for inhalation which comprise microparticles containing an antibiotic and magnesium stearate are useful for the treatment of bacterial infections associated with certain pulmonary diseases. | 06-16-2011 |
| 20110130333 | THERAPEUTIC COMBINATION COMPRISING A PULMONARY SURFACTANT AND A STEROID - Administration of a modified natural surfactant in combination with a corticosteroid is effective for the prevention of bronchopulmonary dysplasia (BPD) and lowers the markers of pulmonary oxidative stress. | 06-02-2011 |
| 20110100361 | PRESSURISED METERED DOSE INHALERS (MDI) - The invention relates to pressurized metered dose inhalers (MDIs) in which all or part of the internal surface is lined with an inert organic coating and which contain a formulation which comprises TA 2005. | 05-05-2011 |
| 20110097409 | PARTICLES COMPRISING A SALT OF 8-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AMINO]ETHYL]-2(1H)-Q- UINOLINONE HAVING IMPROVED ADHESION PROPERTIES FOR POWDER FORMULATIONS FOR INHALATION - Powder particles comprising a pharmaceutically acceptable salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone (carmoterol) having a specific properties exhibit improved adhesion properties for dry powder formulations for inhalation. Such particles are useful for formulations in the form of powders for inhalation and the treatment of certain conditions and diseases. | 04-28-2011 |
| 20110081301 | PHARMACEUTICAL AEROSOL FORMULATIONS OF FORMOTEROL AND BECLOMETASONE DIPROPIONATE - Pharmaceutical formulations comprising beclometasone dipropionate and a salt of formoterol exhibit improved stability and are useful in pressurised metered dose inhalers (pMDIs). | 04-07-2011 |
| 20110070216 | THERAPEUTIC COMBINATION COMPRISING A PULMONARY SURFACTANT AND ANTIOXIDANT ENZYMES - Administration of an exogenous pulmonary surfactant in combination with antioxidant enzymes is effective for the prevention of bronchopulmonary dysplasia (BPD) and decreases the markers of pulmonary oxidative stress. | 03-24-2011 |
| 20110065678 | ISOXAZOLIDINE DERIVATIVES - Novel glucocorticosteroids that are derivatives of isoxazolidine are useful as anti-inflammatory and antiallergic compounds. | 03-17-2011 |
| 20110061651 | FORMOTEROL SUPERFINE FORMULATION - A metal container and a method of preparing a metal container for a pharmaceutical formulation where the active ingredient is formoterol, a stereoisomer of formoterol, and a physiologically acceptable salt of formoterol, in a solution of a liquefied HFA propellant. | 03-17-2011 |
| 20110044913 | 8-HYDROXY-5-[(1R)-1-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AMI- NO]ETHYL]-2(1H)-QUINOLINONE HEMI-FUMARATE - The invention relates to 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]-amino]ethyl]-2(1H)-quinolinone hemi-fumarate salt. The invention also relates to processes for its preparation, pharmaceutical compositions thereof, and to its use as a medicament. | 02-24-2011 |
| 20110039934 | PROCESS FOR THE PREPARATION OF DERIVATIVES OF 1-(2- HALOBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID - Compounds according to formula (IA): | 02-17-2011 |
| 20110003733 | RECONSTITUTED SURFACTANT COMPOSITION CONTAINING ANALOGS OF SURFACTANT PROTEIN B (SP-B) AND SURFACTANT PROTEIN C (SP-C) - Reconstituted pulmonary surfactants comprising a lipid carrier, a combination of polypeptide analog of the native surfactant protein SP-C with a particular polypeptide analog of the native surfactant protein SP-B may be used for the treatment or prophylaxis of RDS and other respiratory disorders. | 01-06-2011 |
| 20100269825 | INHALATION PARTICLES COMPRISING A SALT OF 8-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AMINO] ETHYL]-2(1H)-QUINOLINONE AND A CORTICOSTEROID - Crystalline particles wherein each particle comprises a combination of a pharmaceutically acceptable salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone (carmoterol), and a corticosteroid in a pre-determined and constant ratio are effective for the prevention and treatment of inflammatory or obstructive airways diseases. | 10-28-2010 |
| 20100204256 | 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS - 1-Phenyl-2-pyridinyl alkyl alcohol compounds are effective as inhibitors of the phosphodiesterase 4 (PDE4) enzyme and may be used to prevent and/or treat certain diseases or conditions. | 08-12-2010 |
| 20100184703 | USE OF PEPTIDE DERIVATIVES FOR TREATING PATHOLOGIES RESULTING FROM ISCHEMIA - The inventors have studied the kinetic and hierarchy of activation of apoptogenic caspases during myocardial ischemia and have found that caspase 2 plays a major role during the cardiac pathology by a very fast activation after an ischemic episode. Experiments were carried out on animal models of transitory or permanent myocardial ischemia. It was then observed that electrophysiological remodeling and post-ischemic fibrosis were prevented by using caspase-2 specific inhibitors. The invention is then based on the demonstration that caspase-2 and its activation represents an early and transitory step of the cardiac apoptotic mechanisms resulting from a myocardial ischemic and involved in the development of hypertrophy and cardiac insufficiency. The invention thus relates to a method of treatment of cardiovascular pathologies resulting from ischemia by using certain caspase-2 specific inhibitors. | 07-22-2010 |
| 20100183578 | NITROPROTEIN BIOMARKERS FOR COPD - Specific nitroprotein biomarkers may be used as prognostic and diagnostic tools for COPD. Identification of certain specific nitroprotein biomarkers allows the development of targeted therapies aimed at prevention and treatment of COPD. | 07-22-2010 |
| 20100173880 | ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF - Alkaloid aminoester compounds which act as muscarinic receptor antagonists are useful for the prevention and/or treatment of a broncho-obstructive or inflammatory diseases. | 07-08-2010 |
| 20100099768 | 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - 1-Phenylalkanecarboxylic acid derivatives, the processes for the preparation thereof and the use thereof in the treatment and/or prevention of neurodegenerative diseases such as Alzheimer's disease. | 04-22-2010 |
| 20100098642 | OPTIMISED FORMULATION OF TOBRAMYCIN FOR AEROSOLIZATION - The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium | 04-22-2010 |
| 20100055192 | MICRONIZED PARTICLES OF LOW-DOSAGE STRENGTH ACTIVE AGENTS FOR POWDER FORMULATIONS FOR INHALATION - Micronized particles of a low-dosage strength active ingredient, to be used in dry powder formulations for inhalation, with particular properties can easily and homogenously disperse in a dry powder formulation to be administered by means of a dry powder inhaler device. | 03-04-2010 |
| 20100047184 | PHARMACEUTICAL COMPOSITIONS CONTAINING AN EFFERVESCENT ACID-BASE COUPLE - A pharmaceutical composition in the form of effervescent tablets comprising an active ingredient and an effervescent blend, comprising an acidic component and sodium glycine carbonate as alkaline components. Preferred acid components are fumaric acid, maleic acid, and their salts. Tablets are prepared in normal thermohygrometric conditions and with standard tabletting equipment. A pre-granulation process is also disclosed. | 02-25-2010 |
| 20100035922 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF - Quinuclidine carbonate derivatives act as muscarinic receptor antagonists and are effective for the prevention and/or treatment of a broncho-obstructive or inflammatory diseases. | 02-11-2010 |
| 20100028353 | ANTI-AMYLOID IMMUNOGENIC COMPOSITIONS, METHODS AND USES - Polypeptide based on a tandem array of repeats of the N-terminal 7 amino acids of Aβ42, preferably positioned within the active loop site of a carrier such as bacterial thioredoxin (Trx) are useful for treating and/or preventing Alzheimer's disease. Antibodies raised against these recombinant constructs were found to have a very strong affinity for Aβ42. | 02-04-2010 |
| 20100004173 | RECONSTITUTED SURFACTANTS HAVING IMPROVED PROPERTIES - Reconstituted surfactants comprising a lipid carrier, a polypeptide analog of the native surfactant protein SP-C, and a polypeptide analog of the native surfactant protein SP-B are useful for the treatment and/or prophylaxis of RDS and other respiratory disorders. | 01-07-2010 |
| 20090326231 | PROCESS FOR THE PREPARATION OF 8-HYDROXY-5-[(1R)-1-HYDROXY-2[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AMI- NO]ETHYL]-2(1H)-QUINOLINONE MONOHYDROCHLORIDE - 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride of formula (I) may be conveniently prepared in a diastereomeric pure form from optically pure precursors that are readily available by simple resolution and asymmetric reduction. | 12-31-2009 |
| 20090312426 | PROCESS OF PREPARING DERIVATIVES OF 1-(2-HALOBIPHENYL-4-YL)-CYCLOPROPANECARBOXYLIC ACID - Compounds represented by formula (I): | 12-17-2009 |
| 20090311196 | PHARMACEUTICAL AEROSOL COMPOSITION - Compositions which contain an active ingredient, a propellant containing a hydrofluoroalkane (HFA), a co-solvent, and a low-volatility component are useful for administering the active ingredient via an aerosol. | 12-17-2009 |
| 20090280068 | POLYMORPH OF 8-HYDROXY-5-[(1R)-1-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AM- INO]ETHYL]-2(1H)-QUINOLINONE MONOHYDROCHLORIDE - Crystal form D of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]-amino]ethyl]-2(1H)-quinolinone monohydrochloride is highly crystalline, easy to prepare, and stable. | 11-12-2009 |
| 20090280067 | CRYSTAL FORM OF 8-HYDROXY-5-[(1R)-1-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AM- INO]ETHYL]-2(1H)-QUINOLINONE MONOHYDROCHLORIDE - Crystal form E of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]-amino]ethyl]-2(1H)-quinolinone monohydrochloride is highly crystalline, easy to prepare, and stable. | 11-12-2009 |
| 20090263488 | PRESSURISED METERED DOSE INHALERS CONTAINING SOLUTIONS OF BETA-2 AGONISTS - The present invention relates to a pharmaceutical formulation for use in the administration of 2(1H)-quinolinone derivatives long-acting β | 10-22-2009 |
| 20090258905 | PHOSPHODIESTERASE-4 INHIBITORS BELONGING TO THE TERTIARY AMINE CLASS - Compounds of formula (I): | 10-15-2009 |
| 20090192187 | DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC DRUG - Pharmaceutical formulation in the form of inhalable dry powder comprising particles of a pharmaceutically acceptable salt of 3-[[[(3-fluorophenyl)[(3,4,5-trifluoro phenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo [2.2.2]octane as active ingredient, and particles of a carrier made of a physiologically acceptable pharmacologically-inert material are effective for the prevention and/or treatment of a respiratory disease such as asthma and COPD. | 07-30-2009 |
| 20090186033 | ANTI-AMYLOID IMMUNOGENIC COMPOSITIONS, METHODS AND USES - The present invention provides a recombinant immunogenic obtained by tandem multimerization of a B-cell epitope bearing fragment of Aβ42, within the active loop site of a carrier (display site), preferably bacterial thioredoxin (Trx). Polypeptides bearing multiple copies of Aβ42 fragments, preferably with an interposed amino acid linker, were constructed and injected into mice in combination with an adjuvant. Monoclonal antibodies were made which recognize the immunogenic construct comprising a carrier bearing at least one fragment of Aβ42 within an active loop site of the carrier. The elicited antibodies were found to selectively bind to fibrillar and/or oligomers Aβ within neuritic AD plaques. | 07-23-2009 |
| 20090180969 | PHARMACEUTICAL FORMULATION COMPRISING AN ANTICHOLINERGIC DRUG - Pharmaceutical formulations suitable to be administered by pressurised metered dose inhalers (pMDIs) comprising a salt of 3-[[[(3-fluorophenyl)[(3,4,5-trifluoro phenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane are effective for the prevention and/or treatment of an obstructive airways disease. | 07-16-2009 |
| 20090170903 | ESTER DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS - The invention provides inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to compounds that are new ester derivatives, methods of preparing such compounds, compositions containing them, and therapeutic uses thereof. | 07-02-2009 |
| 20090170758 | COMPOSITIONS COMPRISING PULMONARY SURFACTANTS AND A POLYMYXIN HAVING IMPROVED SURFACE PROPERTIES - Pulmonary surfactants comprising additives, such as polymyxins, that improve their surface tension lowering properties. A method for improving the resistance to inactivation of a modified natural surfactant, such as one containing a lipid extract of minced mammalian lung comprising administering a surfactant in combination with a polymyxin. | 07-02-2009 |
| 20090130026 | PHARMACEUTICAL SOLUTION FORMULATIONS FOR PRESSURISED METERED DOSE INHALERS - The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution. | 05-21-2009 |
| 20090088379 | RECONSTITUTED SURFACTANTS HAVING IMPROVED PROPERTIES - The present invention is directed to a reconstituted surfactant containing a lipid carrier, a polypeptide analog of the native surfactant protein SP-C, and a polypeptide comprising a sequence comprised of repeated units where each unit contains between 3 and 8 hydrophobic amino acid residues and one basic amino acid residue. The invention is also directed to the pharmaceutical compositions thereof and to its use for the prophylaxis and/or treatment of RDS and other respiratory disorders. | 04-02-2009 |
| 20090075892 | Synthetic pulmonary surfactant peptides - The present invention is directed to a reconstituted surfactant comprising a lipid carrier, a polypeptide analog of the native surfactant protein SP-C, and a polypeptide analog of the native surfactant protein SP-B. The invention is also directed to the pharmaceutical compositions thereof and to a use thereof in the treatment or prophylaxis of RDS and other respiratory disorders. | 03-19-2009 |
| 20090048220 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS - Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme. | 02-19-2009 |
| 20090020114 | METERED DOSE INHALER ACTUATOR - Metered dose inhaler actuators for pressurised aerosol containing a formulation of at least one medicament in a liquefied propellant gas which comprise:
| 01-22-2009 |
| 20090012284 | Process for the Preparation of a Piroxicam: Betacyclodextrin Inclusion Compound - The present invention relates to a process for the preparation of an inclusion compound of piroxicam with β-cyclodextrin by spray-drying, applicable on a pilot or industrial scale. The obtained product have optimal physico-chemical characteristics as well as technological and biopharmaceutical properties and it is suitable for preparing solid pharmaceutical compositions for the oral administration. | 01-08-2009 |
| 20080287480 | Therapeutic Combination Comprising a Nmda Receptors Blocker and a Narcotic Analgesic Substance - The invention relates to a medicament comprising a combination of a substance that blocks both the ion channel associated to NMDA receptors and MAO enzymes and a narcotic analgesic substance, preferably a fixed combination, pharmaceutical compositions thereof, and to the use thereof for the treatment of subjects suffering of various types of pain and/or for inhibiting the development of tolerance, and/or physical dependence on a narcotic analgesic substance. | 11-20-2008 |
| 20080261932 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND/OR TREATMENT OF AN EXACERBATION OF ASTHMA - The present invention relates to the use of a composition comprising:
| 10-23-2008 |
| 20080247965 | PRESSURISED METERED DOSE INHALERS (MDI) - The invention relates to pressurized metered dose inhalers (MDIs) in which all or part of the internal surface is lined with an inert organic coating and which contain a formulation which comprises TA 2005. | 10-09-2008 |
| 20080242589 | SYNTHETIC LIPID MIXTURES FOR THE PREPARATION OF A RECONSTITUTED SURFACTANT - The invention relates to reconstituted surfactants consisting of artificial phospholipids and peptides able to lower the air-liquid surface tension, more particularly to reconstituted surfactants comprising special phospholipid mixtures and artificial peptides which are analogues of the natural surfactant SP-C protein for the treatment of respiratory distress syndrome (RDS) and other diseases relating to pulmonary surfactant dysfunctions. | 10-02-2008 |
